BIRMINGHAM, Ala., Feb. 7, 2019 /PRNewswire/ -- Encompass Health Corporation (EHC), a national leader in integrated healthcare services, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies, today reported its results of operations for the fourth quarter ended December 31, 2018.
"We ended 2018 with another quarter of strong operating and financial results," said Mark Tarr, President and Chief Executive Officer of Encompass Health. "Through the course of 2018, we met or exceeded our objectives for growth and quality, and we made substantial gains on initiatives such as clinical collaboration, enhanced data analytics, and the development of post-acute solutions. The investments we are making in our business position us well to meet the growing demand for the services we provide."
Consolidated results
Growth |
||||||||||||||
Q4 2018 |
Q4 2017 |
Dollars |
Percent |
|||||||||||
(In Millions, Except per Share Data) |
||||||||||||||
Net operating revenues |
$ |
1,096.0 |
$ |
1,008.8 |
$ |
87.2 |
8.6 |
% |
||||||
Income from continuing operations attributable |
0.26 |
0.61 |
(0.35) |
(57.4) |
% |
|||||||||
Adjusted earnings per share |
0.80 |
0.70 |
0.10 |
14.3 |
% |
|||||||||
Cash flows provided by operating activities |
178.4 |
151.4 |
27.0 |
17.8 |
% |
|||||||||
Adjusted EBITDA |
221.8 |
208.2 |
13.6 |
6.5 |
% |
|||||||||
Adjusted free cash flow |
113.3 |
91.5 |
21.8 |
23.8 |
% |
|||||||||
Year Ended December 31, |
||||||||||||||
2018 |
2017 |
|||||||||||||
Cash flows provided by operating activities |
762.4 |
658.3 |
104.1 |
15.8 |
% |
|||||||||
Adjusted free cash flow |
538.1 |
468.7 |
69.4 |
14.8 |
% |
Revenue growth was driven by volume and pricing growth in the inpatient rehabilitation segment and volume growth in the home health and hospice segment. See the "Other Information" section of this release for discussion of the Company's adoption of a new accounting standard for revenue recognition in 2018.
Income from continuing operations attributable to Encompass Health per diluted share decreased due to the accrual of loss contingencies of $52 million, or $0.52 per share, included in the line item government, class action, and related settlements, $48 million, or $0.48 per share, of which relates to on-going discussions with the United States Department of Justice, as discussed below.
The increase in adjusted earnings per share resulted primarily from increased revenue and a lower effective tax rate resulting from income tax reform.
Growth in cash flows provided by operating activities and adjusted free cash flow resulted primarily from revenue growth and favorable working capital changes.
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
"The strength and consistency of our free cash flow generation was again evident in the fourth quarter," said Doug Coltharp, Executive Vice President and Chief Financial Officer of Encompass Health. "For 2018, adjusted free cash flow of approximately $538 million was sufficient to fund capacity expansions in both business segments and shareholder distributions, while still reducing funded debt."
Inpatient rehabilitation segment results
Growth |
||||||||||||||
Q4 2018 |
Q4 2017 |
Dollars |
Percent |
|||||||||||
Net operating revenues: |
(In Millions) |
|||||||||||||
Inpatient |
$ |
822.8 |
$ |
776.9 |
$ |
45.9 |
5.9 |
% |
||||||
Outpatient and other |
22.9 |
25.5 |
(2.6) |
(10.2) |
% |
|||||||||
Total segment revenue |
$ |
845.7 |
$ |
802.4 |
$ |
43.3 |
5.4 |
% |
||||||
(Actual Amounts) |
||||||||||||||
Discharges |
45,498 |
43,910 |
1,588 |
3.6 |
% |
|||||||||
Same-store discharge growth |
1.9 |
% |
||||||||||||
Net patient revenue per discharge |
$ |
18,084 |
$ |
17,693 |
$ |
391 |
2.2 |
% |
||||||
(In Millions) |
||||||||||||||
Adjusted EBITDA |
$ |
211.7 |
$ |
207.1 |
$ |
4.6 |
2.2 |
% |
Outpatient and other revenue decreased due primarily to continued closures of hospital-based outpatient programs.
Revenue reserves (formerly bad debt expense) as a percent of revenue increased 50 basis points to 1.5% in the fourth quarter of 2018 primarily due to new pre-payment claims denials (net of recoveries) and post-payment reserves for new Medicare Advantage contractual claims reviews with one managed care organization.
Home health and hospice segment results
Growth |
||||||||||||||
Q4 2018 |
Q4 2017 |
Dollars |
Percent |
|||||||||||
Net operating revenues: |
(In Millions) |
|||||||||||||
Home health |
$ |
215.3 |
$ |
186.3 |
$ |
29.0 |
15.6 |
% |
||||||
Hospice |
35.0 |
20.1 |
14.9 |
74.1 |
% |
|||||||||
Total segment revenue |
$ |
250.3 |
$ |
206.4 |
$ |
43.9 |
21.3 |
% |
||||||
Home Health Metrics |
||||||||||||||
(Actual Amounts) |
||||||||||||||
Admissions |
35,151 |
31,766 |
3,385 |
10.7 |
% |
|||||||||
Same-store admissions growth |
5.4 |
% |
||||||||||||
Episodes |
64,037 |
56,625 |
7,412 |
13.1 |
% |
|||||||||
Same-store episode growth |
6.5 |
% |
||||||||||||
Revenue per episode |
$ |
2,972 |
$ |
2,976 |
$ |
(4) |
(0.1) |
% |
||||||
(In Millions) |
||||||||||||||
Adjusted EBITDA |
$ |
44.1 |
$ |
34.4 |
$ |
9.7 |
28.2 |
% |
Hospice revenue increased primarily due to acquisitions and same-store admission growth of 8.6%.
Corporate general and administrative expenses
Q4 2018 |
% of |
Q4 2017 |
% of |
||||||||
(In Millions) |
|||||||||||
General and administrative expenses, |
$ |
34.0 |
3.1% |
$ |
33.3 |
3.3% |
|||||
General and administrative expenses decreased as a percent of consolidated revenue primarily due to operating leverage resulting from revenue growth.
During the fourth quarter of 2018, the Company invested $2.6 million in its rebranding and name change, all of which was included in general and administrative expenses. During the fourth quarter of 2017, the Company invested $2.5 million in its rebranding and name change.
Full-year consolidated results
Full-Year |
Growth |
|||||||||||||
2018 |
2017 |
Dollars |
Percent |
|||||||||||
(in millions, except per share data) |
||||||||||||||
Net operating revenues |
$ |
4,277.3 |
$ |
3,913.9 |
$ |
363.4 |
9.3 |
% |
||||||
Income from continuing operations attributable |
2.92 |
2.69 |
0.23 |
8.6 |
% |
|||||||||
Adjusted earnings per share |
3.63 |
2.76 |
0.87 |
31.5 |
% |
|||||||||
Adjusted EBITDA |
901.0 |
823.1 |
77.9 |
9.5 |
% |
See the attached supplemental information for additional details regarding these calculations.
Reserve for potential government settlement
Based on recent discussions with DOJ, the Company established a reserve of $48 million in the fourth quarter of 2018 for the potential settlement of the investigation initially disclosed in March 2013. As previously disclosed, since 2013, the Company has been cooperating with an investigation of alleged improper or fraudulent Medicare and Medicaid claims. The investigation, under the direction of DOJ, has been pending six years. The Company is aware of no evidence of fraud, falsity or wrongdoing. However, based on recent discussions with DOJ and having considered the burdens and distractions associated with continuing the investigation and the likely costs of future litigation, the Company now estimates a settlement value of $48 million. Discussions are ongoing, and until they are concluded, there can be no certainty about the nature, timing or likelihood of a settlement. No tax benefit related to the loss contingency reserve has been recorded as it is not possible to determine tax deductibility.
2019 guidance
In a current report on Form 8-K dated January 7, 2019, the Company provided its preliminary guidance ranges for 2019. The Company is confirming the following guidance ranges.
Full-year 2019 guidance ranges |
|
(in millions, except per share data) |
|
Net operating revenues |
$4,500 to $4,600 |
Adjusted EBITDA |
$925 to $945 |
Adjusted earnings per share from continuing operations |
$3.71 to $3.85 |
For additional considerations regarding the Company's 2019 guidance ranges, see the supplemental information posted on the Company's website at http://investor.encompasshealth.com. See also the "Other Information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 9:00 a.m. Eastern Time on Friday, February 8, 2019 to discuss its results for the fourth quarter of 2018. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 877 587-6761 and giving the pass code 4768167. International callers should dial 706 679-1635 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
As a national leader in integrated healthcare services, Encompass Health (EHC) offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.